Browse the evidence

Lifestyle modifications have limited lasting effects on weight and blood pressure reduction.

Practitioners should consider the limited effectiveness of lifestyle changes alone for weight and BP management.

The review intends to indirectly compare the adverse events of available glucagon-like peptide-1 receptor agonist pharmaceuticals.

The review may provide insights into the safety profile of these medications for practitioners.

Pharmacological classes of metabolic drugs have unexpected and often beneficial effects on cardiovascular outcomes.

Consider the use of metabolic drugs in managing cardiovascular health.

Obesity, sarcopenia, and heart failure with preserved ejection fraction (HFpEF) are interconnected through the adipokine axis.

Understanding the link between these conditions can guide treatment strategies.

A maladaptive adipokine milieu is associated with endothelial dysfunction, myocardial stiffening, and muscle atrophy in HFpEF.

Recognizing this cycle can inform targeted interventions.

Emerging translational applications include diagnostic and prognostic adipokine signatures and therapeutic impacts of GLP-1 receptor agonists.

These applications could enhance clinical practice in managing HFpEF.

Current pharmacological treatments aim to restore energy balance by targeting disrupted pathways.

Practitioners should be aware of pharmacological options that target energy balance in obesity management.

Categories of weight change did not differ for change in physical activity or dietary intake.

Weight change categories may not influence physical activity or dietary intake adjustments.

Intervention conditions did not differ for change in weight, physical activity, dietary intake, and measures of hunger, dietary disinhibition, and total dietary restraint.

Different physical activity interventions may not lead to significant differences in weight or dietary behaviors.

BMI is not sufficient to define obesity; pathophysiology and the impact of mechanical, metabolic, and psychological complications must be considered.

Practitioners should consider multiple factors beyond BMI when assessing obesity.

Rates of obesity have doubled for adults and quadrupled for adolescents since the 1990s.

Practitioners should be aware of the rising obesity rates to address this public health issue.

There needs to be a cultural shift to accept obesity as a disease and improve access to effective treatments sooner.

Advocacy for policy changes and education on obesity as a disease is essential.

Evidence suggests a reduced incidence of several gastrointestinal cancers with GLP-1 receptor agonist use.

GLP-1 receptor agonists may be considered for patients at risk of gastrointestinal cancers.

The development of oral formulations such as oral Semaglutide is expected to provide convenience for patients and enhance their willingness to receive treatment.

Practitioners should consider the potential of oral Semaglutide to improve patient adherence to obesity treatment.

Patient factors potentially contributing to increased aspiration risks included a higher body mass index, type 2 diabetes mellitus, gastro-oesophageal reflux disease, emergency case, and time from GLP-1 agonist cessation.

Understanding these risk factors can help clinicians better assess patients on GLP-1 agonists before surgery.

GLP-1 receptor agonists have good safety and tolerability compared to traditional hypoglycemic drugs.

Practitioners can consider GLP-1 receptor agonists as a safer alternative for diabetes treatment.

Small molecule agonists of GLP-1 receptor have advantages of low cost and oral administration compared to peptide drugs.

Practitioners may consider small molecule GLP-1 receptor agonists as a cost-effective and convenient treatment option.

The tolerability and key adverse events associated with these AOMs appear to be acceptable in randomized controlled trials.

Clinicians can be reassured about the safety profile of newer AOMs based on trial data.

Fecal transplant may have a preventive role in diabetes progression.

Consider the potential of fecal transplants in diabetes prevention strategies.

There was no difference between the intervention periods regarding mean blood glucose (MBG), time in range (TIR), and hypoglycemic events.

GTSS does not negatively impact overall glucose control or increase hypoglycemic risk.

The current evidence for interventions that address food insecurity and obesity is mixed and limited in scope.

More rigorous trials are needed to determine effective interventions for obesity in food-insecure populations.

Success in weight loss was independent of the quantity and quality of carbohydrate intake.

Weight loss programs may not need to focus on carbohydrate quantity or quality.

Increased consumption of simple sugars and fats is directly related to changes in the composition and functions of gut microbiota.

Dietary recommendations should consider the impact of sugar and fat on gut health.

Subjects with the highest scores on the 'high-protein and high-carbohydrate' dietary patterns had higher odds of cardiovascular disease (CVD) than those with the lowest scores (OR: 2.89, 95% CI: 2.11–3.96).

Practitioners should consider advising patients with T2D to be cautious about high-protein and high-carbohydrate dietary patterns due to their association with increased CVD risk.